Darim Donepezil 5 mg Tablets (Donepezil Hydrochloride Monohydrate)
Donepezil Hydrochloride Hydrate 5.22mg
Tablet · Prescription medication
Darim Biotech Co., Ltd.
MFDS item code 201903119 · Approved 2019.05.14
This product's status changed to Expired on 2024.05.14. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of symptoms of Alzheimer-type dementia
Used for the treatment of Alzheimer's dementia symptoms.
○ Adults: Administer 5 mg of donepezil hydrochloride once daily before bedtime. If sleep disturbances such as abnormal dreams, nightmares, or insomnia occur, consider taking this medicine in the morning. Since donepezil reaches steady-state concentrations 15 days after administration and the incidence of adverse reactions may be affected by the rate of dose increase, administer the 5 mg dose for 4~6 weeks. After evaluating the clinical response during this period, the dose may be increased to 10 mg. When increasing the dose to 10 mg per day, administer with attention to gastrointestinal adverse reactions. When treatment with this medicine is discontinued, its effect gradually diminishes, and no rebound effect occurs following abrupt discontinuation. ○ Female patients aged 85 years and older with low body weight: Careful monitoring is required because adverse reactions occur more frequently. Elderly women with low body weight should not exceed 5 mg per day.
○ Children: There is no experience with use in children.
This medicine contains Donepezil Hydrochloride Monohydrate as the active ingredient and is used for the treatment of Alzheimer's dementia symptoms. First, it should not be used in patients who have allergies to Donepezil Hydrochloride or piperidine derivatives, or to any other components of this drug. Additionally, pregnant women or women who may become pregnant, as well as nursing mothers, should not take this medication. Since it contains lactose, patients with hereditary lactose intolerance or related disorders should also avoid it. Caution is required when administering this drug to patients with heart diseases, especially those with bradycardia or heart conduction disorders, as it may lower heart rate or induce arrhythmia. Patients taking non-steroidal anti-inflammatory drugs or with a history of peptic ulcer disease should closely monitor their gastrointestinal condition. Patients with a history of asthma or obstructive pulmonary disease should also be careful, as bronchospasm and increased mucus secretion may occur. Patients with extrapyramidal disorders such as Parkinson’s disease should exercise caution, as symptoms may worsen. Furthermore, caution is advised for those allergic to Tartrazine (Yellow No. 5). Serious side effects such as cardiovascular adverse reactions (bradycardia, heart block, myocardial infarction, etc.), gastrointestinal bleeding, liver dysfunction, cerebrovascular issues, movement disorders, neuroleptic malignant syndrome, rhabdomyolysis, acute renal failure, acute pancreatitis, respiratory distress, and sudden death may occur. If these symptoms arise, discontinue the medication immediately and consult a healthcare professional. More common side effects include nausea, vomiting, diarrhea, appetite loss, dizziness, insomnia, headache, fatigue, muscle pain, which are mostly mild and temporary. However, if symptoms are severe or persist, consult a doctor. Patients with heart conduction disorders or prolonged QT interval are at risk of cardiac arrhythmias; therefore, an electrocardiogram may be necessary. Additionally, this medication may interact with several drugs, so inform healthcare providers if taking other medications. This drug should not be used during pregnancy unless under special circumstances, and nursing mothers are advised to discontinue breastfeeding while taking this medication. Safety in children has not been established, so it is not administered to pediatric patients. In case of overdose, symptoms such as nausea, vomiting, bradycardia, hypotension, respiratory depression, and convulsions may occur, and immediate medical attention should be sought. Atropine may be used as an antidote, so follow medical advice. Store this medication out of the reach of children, and be cautious not to transfer it to other containers, as this could lead to a decrease in quality or accidents.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air entry and should be kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the efficacy of the drug and prevent deterioration.
Yellow round film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Donepezil Hydrochloride Hydrate 5.22mg
Tablet · Prescription medication
Darim Biotech Co., Ltd.

Donepezil Hydrochloride 5mg
Tablet · Prescription medication
HanDoc Co., Ltd.

Donepezil Hydrochloride 10mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Donepezil Hydrochloride Hydrate 10.43mg
Tablet · Prescription medication
IYun Pharmaceuticals Co., Ltd.

Donepezil Hydrochloride Hydrate 10.43mg
Tablet · Prescription medication
Yuhan Corporation

Donepezil Hydrochloride Hydrate 10.43mg
Tablet · Prescription medication
Myungmoon Pharmaceutical Co., Ltd.

Donepezil Hydrochloride Hydrate 10.43mg
Tablet · Prescription medication
HK inno.N Co., Ltd.
Donepezil Hydrochloride 10mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.